Country: Canada
Language: English
Source: Health Canada
TIOTROPIUM (TIOTROPIUM BROMIDE MONOHYDRATE)
BOEHRINGER INGELHEIM (CANADA) LTD LTEE
R03BB04
TIOTROPIUM BROMIDE
18MCG
CAPSULE
TIOTROPIUM (TIOTROPIUM BROMIDE MONOHYDRATE) 18MCG
INHALATION
10/30; 1 HANDIHALER
Prescription
ANTIMUSCARINICS ANTISPASMODICS
Active ingredient group (AIG) number: 0148683001; AHFS:
APPROVED
2002-11-20
_Product Monograph _ _ _ _SPIRIVA (tiotropium) _ _Page 1 of 42_ PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION Pr SPIRIVA® Tiotropium inhalation powder capsules Inhalation powder capsules, 18 mcg tiotropium (as tiotropium bromide monohydrate), Oral Inhalation Bronchodilator (Long-Acting Muscarinic Antagonist (LAMA)) Capsules to be used only with the supplied HandiHaler® inhalation device ATC R03BB04 Boehringer Ingelheim (Canada) Ltd. 5180 South Service Road Burlington, Ontario L7L 5H4 Date of Initial Authorization: NOV 20, 2002 Date of Revision: APR 22, 2022 Submission Control Number: 258194 BICL #0251-09 Spiriva® and HandiHaler® are registered trademarks of Boehringer Ingelheim International GmbH, used under license. _ _ _Product Monograph _ _ _ _SPIRIVA (tiotropium) _ _Page 2 of 42_ RECENT MAJOR LABEL CHANGES 4 Dosage and Administration 7 Warnings and Precautions 04/2022 04/2022 TABLE OF CONTENTS SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF AUTHORIZATION ARE NOT LISTED . RECENT MAJOR LABEL CHANGES............................................................................................ 2 TABLE OF CONTENTS .............................................................................................................. 2 PART I: HEALTH PROFESSIONAL INFORMATION ..................................................................... 4 1 INDICATIONS .............................................................................................................. 4 1.1 Pediatrics .......................................................................................................... 4 1.2 Geriatrics........................................................................................................... 4 2 CONTRAINDICATIONS ................................................................................................. 4 4 DOSAGE AND ADMINISTRATION................................................................................. 4 4.1 Dosing Considerations .............................. Read the complete document